* cobas® i 601 analytical unit (Mass Spec) is under development, not approved by any regulatory body, and not commercially available.
Catch a glimpse of our future fully automated, standardized liquid chromatography-mass spectrometry (LC-MS) solution: the cobas® Mass Spec.
Recently unveiled at EuroMedLab 2023, our mass spectrometry analyzer is designed to seamlessly integrate into clinical chemistry and immunochemistry testing as part of cobas® pro integrated solutions, as well as lab automation & IT.** Are you as thrilled as we are about this innovative solution? Stay informed by subscribing to our updates.
Register now to receive the latest launch updates.
Join us on this journey and discover new possibilities for your lab. With a planned broad in-vitro diagnostics (IVD) testing menu, it is designed to replicate the user experience of established immunoassay or clinical chemistry analyzers.
This solution has the potential to bring the core lab of the future to life. Watch this informative video that showcases the cobas® Mass Spec solution—designed to be a fully integrated, high-throughput system with an extensive menu, at launch.
Join us on this journey and discover new possibilities for your lab.
Join our mailing list to learn more about cobas® Mass Spec solution and to receive up-to-date information about its availability in your region.
*cobas® i 601 analytical unit (Mass Spec) and Ionify® reagent line are under development, not approved by any regulatory body, and not commercially available. Contact the local Roche Diagnostics representative to enquire on the expected availability timeline for your country.
** At launch cobas® Mass Spec will be available in a stand-alone configuration only. All other configurations including clinical chemistry and immunochemistry analytical units will be available at a later date.
